Rivaroxaban Oral Tablet

DRUG4 trials

Sponsors

Swiss Paraplegic Research, Nottwil, Herlev and Gentofte Hospital, Joon Bum Kim

Conditions

AORTIC VALVE DISEASESAtrial FibrillationAtrial FlutterDeep Vein ThrombosisPulmonary EmbolismSpinal Cord InjuriesThromboembolism

Phase 4

Absorption of Rivaroxaban in Patients With Cervical Spinal Cord Injury

WithdrawnNCT02970773

Swiss Paraplegic Research, NottwilSpinal Cord Injuries, Thromboembolism

Start: 2017-12-04End: 2018-12-07Updated: 2019-01-22

The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation

Active, not recruitingNCT03129490

Herlev and Gentofte HospitalAtrial Fibrillation, Atrial Flutter

Start: 2023-04-01End: 2027-10-30Target: 11000Updated: 2025-05-18

The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)

Active, not recruitingNCT03129555

Herlev and Gentofte HospitalDeep Vein Thrombosis, Pulmonary Embolism

Start: 2023-04-01End: 2029-03-31Target: 5000Updated: 2025-05-15

Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve Replacement

RecruitingNCT04258488

Joon Bum KimAORTIC VALVE DISEASES, Thromboembolism

Start: 2022-02-21End: 2028-12-30Target: 1300Updated: 2025-12-29

Related Papers

Antithrombotic Management and Long-Term Outcomes of Patients with Atrial Fibrillation. Insights from CRAFT Trial

Journal of Clinical Medicine2021-04-193 citations

Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients

Stroke2018-12-01308 citations